Mass General Brigham’s Tango Therapeutics TNGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$8.84M Hold
354,192
– – 1.94% 5
2026
Q2
$11.1M Hold
354,192
– – 3.07% 4
2026
Q1
$7.41M Hold
354,192
– – 1.58% 4
2025
Q4
$3.14M Buy
+354,192
New +$3.05M 0.39% 5
2024
Q3
$2.73M Hold
354,192
– – 6.25% 4
2024
Q2
$3.04M Hold
354,192
– – 14.79% 3
2024
Q1
$2.81M Buy
+354,192
New +$3.8M 4.92% 4

Other funds holding TNGX

Mass General Brigham's TNGX Position: Q3 2026 in Review

Mass General Brigham held its Tango Therapeutics (TNGX) position steady in Q3 2026 at 354,192 shares worth $8.84M. The position accounts for 1.94% of the portfolio, ranked #5.

Mass General Brigham first reported a position in TNGX in Q1 2024 and has held it in 7 quarters since. The position peaked at $11.1M in Q2 2026. 257 funds tracked by Wall St. Rank hold TNGX as of Q3 2026.

  • Mass General Brigham held 354,192 shares of Tango Therapeutics worth $8.84M as of Q3 2026.
  • Mass General Brigham left its Tango Therapeutics share count unchanged in Q3 2026.
  • Tango Therapeutics made up 1.94% of Mass General Brigham's portfolio in Q3 2026, its #5 holding.
  • Mass General Brigham first reported a position in Tango Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • Mass General Brigham's Tango Therapeutics position peaked at $11.1M in Q2 2026.
  • 257 funds tracked by Wall St. Rank held Tango Therapeutics as of Q3 2026.

Based on Mass General Brigham's 13F filing for Q3 2026, filed 3 Nov 2026.